Abstract CVN (cyanovirin-N), a small lectin isolated from cyanobacteria, exemplifies a novel class of anti-HIV agents that act by binding to the highly glycosylated envelope protein gp120 (glycoprotein 120), resulting in inhibition of the crucial viral entry step. In the present review, we summarize recent work in our laboratory and others towards determining the crucial role of multivalency in the antiviral activity, and we discuss features that contribute to the high specificity and affinity for the glycan ligand observed in CVN. An integrated approach that encompasses structural determination, mutagenesis analysis and computational work holds particular promise to clarify aspects of the interactions between CVN and glycans.
Introduction
The surface of HIV and other enveloped viruses is decorated by heavily glycosylated envelope proteins, resulting in a glycan coat that covers the surface of the virus. Glycosylation is attained through exploitation by the virus of the host's biosynthetic machinery, which functionalizes specific sites encoded in the viral protein's sequence. Such functionalization affects both the folding of the viral glycoproteins and viral transmission; furthermore, it creates a 'self-like' surface that screens the virus from the immunological surveillance of the host [1] . The role of glycosylation has been well documented in particular for HIV. The HIV envelope glycoprotein gp120 (glycoprotein 120) is characterized by an unusually high level of N-glycosylation: approximately 25 glycosylation sites found on its sequence result in glycans, accounting for 50% of its molecular mass [1] . The high density of N-glycosylation sites and the presence of Manα(1→2)Manα termini not usually found in host proteins constitute an interesting therapeutic target [2] . Several lectins bind to mannose-rich glycans on gp120 and have been shown to inhibit viral entry in laboratory-adapted strains of HIV as well as in primary isolates [3] [4] [5] [6] [7] .
Among these lectins, CVN (cyanovirin-N), a small (11 kDa) lectin isolated from the cyanobacterium Nostoc ellipsosporum [8] , was discovered through high-throughput screening of extracts from plant, algal and bacteria against several viruses, including HIV-1 [9] , and later isolated by anti-HIV bioassay-guided fractionation [8] . Mechanistic studies showed that CVN binds to the oligomannosides of gp120, and presumably disrupts receptor-induced conformational changes that would lead to membrane fusion [5, [10] [11] [12] [13] . Furthermore, CVN inhibits HIV binding to the DC-SIGN (dendritic cell-specific intracellular adhesion molecule-3 grabbing non-integrin) receptor on dendritic cells as well as the crucial transfer step from dendritic cells to susceptible CD4
+ cells, and is thus being investigated as a microbicidal agent to prevent mucosal HIV transmission [14] . In contrast with most lectins, which usually display low levels of affinity and specificity resulting in promiscuous binding to related glycans, CVN recognizes exclusively oligomannoses containing the Manα(1→2)Manα moiety.
Over the years, several groups have investigated the structure, the relationship between multivalency and antiviral activity, and the determinants of carbohydrate recognition in CVN. Although several questions remain unanswered, the protein is emerging as a convenient model system to investigate glycan-protein interactions and to test computational approaches to glycan recognition.
Structure
The solution structure of CVN revealed a monomeric protein with a previously unobserved fold consisting mainly of β-strands and possessing two domains, A and B, which share a high degree of symmetry [15] . Each domain contains a single carbohydrate-binding site, separated by ∼40 Å (1 Å = 0.1 nm) in the monomeric structure [16, 17] . Binding of the Man 8 and Man 9 glycans by CVN occur specifically through the α(1→2)-linked di-and tri-mannose moieties of the D1 and D3 arms, with domain A preferentially binding trimannose [18] . Both domains have affinity for the Manα(1→2)Manα ligand, the minimal structural requirement for recognition by CVN; whereas, of the two domains, B possesses a higher affinity for the dimannose ligand [17] . Aside from the monomeric form, CVN has been observed in X-ray crystal structures and in solution to possess the ability to dimerize by the phenomenon of domain-swapping. Domain-swapped dimers form by exchanging portions of two monomeric subunits through extension of a hinge region spanning residues 49-54 [19, 20] . The ability of CVN to dimerize increases its valency by doubling the number of carbohydrate-binding sites and potentially augmenting its potency.
Probing the role of multivalency in binding to gp120
In analogy to other carbohydrate-lectin recognition processes involving multidentate interactions [21] , several gp120-binding lectins appear to rely on multivalency. Antiviral lectins unrelated to CVN form highly symmetrical and intertwined homodimers, with each monomer containing two independent carbohydrate-binding domains [22] . One of the few broadly neutralizing antibodies isolated from infected patients, IgG1 2G12, was found to bind specifically to clustered oligomannoses on gp120. The antibody forms a unique domain-swapped structure by exchanging the V H domains, creating an extended binding surface that can accommodate the clustered arrangement of dimannose termini [23, 24] .
In cyanovirin, multiple binding interactions with the oligomannoside target could be achieved by simultaneously engaging both domains A and B in the monomeric form, and/or by engaging two or more binding sites in the domainswapped dimer form. This hypothesis is supported by the difference observed in binding linear oligomannosides and glycosylated gp120. Whereas each domain, A and B, binds di-and tri-mannose independently with dissociation constants in the micromolar range, monomeric CVN binds gp120 at nanomolar concentrations, suggesting an avidity effect. Further evidence of multivalency is the agglutination resulting from the interaction of CVN at micromolar concentrations with multidentate mannosides such as Man 9 and Man 8 [25] .
To address these issues unequivocally, we designed a novel mutant, P51G-m4-CVN (Figure 1 ), which contains a single high-affinity carbohydrate-binding site (domain B), folds exclusively as a monomer under physiological conditions and is more stable than wt (wild-type) CVN. The protein was designed by merging two sets of mutations, four in order to abolish glycan binding to domain A [26] and a hinge region mutation, P51G, which had been shown to stabilize the monomer and prevent domain swapping [27] . P51G-m4-CVN was designed to clarify whether the presence of one mannose-binding site is sufficient for antiviral activity or whether multivalent interactions, either via the two sites on each cyanovirin molecule or via the four possible sites on the domain-swapped form, are necessary. This issue had been controversial, owing to the difficulties in clearly discriminating between the possible models, and complicated further by the slight selectivity of each domain for a different linear oligomannoside [16, 18, [25] [26] [27] [28] . As designed, P51G-m4-CVN contains a single functional carbohydratebinding site (domain B) and folds exclusively as a monomer under physiological conditions; it is possible to obtain the domain-swapped form by unfolding and refolding at millimolar protein concentrations [29] . The high-resolution X-ray structure of the free and dimannose-bound complex revealed important details on the binding mode [29, 30] . We investigated the interaction of P51G-m4-CVN with gp120 by ELISA, revealing a decrease in apparent affinity of ∼100-fold compared with wt CVN (Table 1) ; high-affinity binding can be rescued by forming the domain-swapped dimer. This was the first evidence linking multivalency and high-affinity binding to gp120; we further tested the antiviral activity of P51G-m4-CVN, revealing loss of activity at concentrations as high as 5 μM. In contrast, wt CVN inhibits HIV with an EC 50 of approximately 0.1 nM.
The complete loss of antiviral activity in P51G-m4-CVN demonstrated the importance of multivalent interactions with the viral gp120, confirming one of the mechanisms that had been hypothesized for antiviral lectins, as illustrated in Figure 2 (c) [12, 13, 22, 31] . Our conclusions were corroborated by independent studies of a complementary mutant, CVN mutDB , in which the binding site on domain B had been abolished on the background of P51G: this mutant is also inactive against HIV [18] .
We then explored whether constructs containing two copies of domain B could recover biological function. Mutants S52P-m4-CVN and 50Q-m4-CVN, which form obligate domain-swapped dimers, restore multivalency because they encompass two functional B domains, while containing four mutations that abolish binding in each domain A [32] . We found that these mutants bind gp120 at nanomolar concentrations, and display significant anti-HIV activity. Unfortunately, the hinge mutations resulted in reduced thermostability, which affected their performance in antiviral assays performed at 38
• C; Q50-m4-CVN displayed an EC 50 of 320 nM, compared with 0.9 nM observed for wt CVN (Table 1) . More complete restoration of activity to levels similar to that of CVN was observed in covalent dimers of monomeric constructs containing inactive domain A and linked by an intermolecular disulfide bond. In these constructs, multivalency is restored by the presence of two intact copies of domain B (BB ) in the dimer, and results in potent antiviral activity (IC 50 of 6 nM compared with 0.7 nM for wt CVN). A related construct containing two copies of intact domain A (AA ) dimerized via domain-swapping has a somewhat diminished IC 50 of 60 nM; it is unclear whether these differences arise from the identity of the intact domains in the dimer (BB compared with AA ) or from the stability of the dimers (covalent compared with non-covalent dimers) [33] .
The ability of intact CVN to form domain-swapped dimers [34] and higher-order oligomers [35] suggests that these species may contribute to antiviral activity through glycan cross-linking [31] . In that case, it may be possible to improve further on the potent antiviral activity of CVN by stabilizing dimeric species, and thus augmenting its multivalency. Mayo and co-workers designed tandem repeats of CVN to create covalently linked dimers, which form structures highly reminiscent of the domain-swapped dimers observed for wt CVN [36] . The tandem repeat dimer CVN 2 L0, which contains two copies of wt CVN and thus has all four binding sites intact (A, A , B, B ) , showed improved neutralization activity compared with wt CVN; the dimer also showed extensive cross-clade activity. Obliteration of binding domains within CVN 2 demonstrated a linear correlation between number of domains and activity. Remarkably, however, no improvements in activity were observed for constructs containing three or four copies of linked CVN, suggesting that the interdomain distances in the domain-swapped dimer of CVN are optimal for binding to gp120.
CVNHs: a family of cyanovirin homologue proteins
A family of homologues of cyanovirin (CVNHs) has been identified by sequence homology searches and fold recognition methods in eukaryotic organisms such as filamentous ascomycetes and seedless plants [37] . In analogy to cyanovirin, most members contain two sequential repeats of approximately 50 residues in which several positions are conserved. All proteins are predicted to form a β-sheet fold with a 3D structure similar to that of wt CVN. Most of the conserved residues are located in the predicted hydrophobic core shared by the two repeats. In addition, four hydrophilic amino acids involved in interstrand hydrogen bonds are conserved. The residues lining the sugar-binding pocket are not as conserved.
To date, six members of the family have been characterized [38] [39] [40] [41] , confirming the predicted 3D structure to be almost identical with that of CVN. The five type I CVNHs are monomeric, as expected from the lack of proline at the position corresponding to residue 51 of CVN. Each member binds oligomannose at high micromolar concentrations, as assessed by monitoring chemical shift perturbation; however, these lectins are significantly more promiscuous than CVN. It is possible that the sequence variability correlates with differences in binding specificities. It should be noted, however, that the internal homology between the two domains of cyanovirin is quite low, yet each binds to Manα(1→2)Manα termini with similar affinities [16, 38] .
In a few members of the CVNH family, the cyanovirin repeats are associated with other unrelated domains. For instance, type I CVNHs described above contain two cyanovirin modules in sequence, whereas in type III, the two repeats of cyanovirin are separated by a LysM chitin-binding domain connected through flexible linkers. The structure of a type III CVNH, MoCVNH-LysM, has been solved [39] . The structure of the homologue is that of an overall hammerhead fold, in which LysM protrudes from the midpoint of the cyanovirin structure, with the cyanovirin domain binding dimannose at millimolar concentrations.
The lessons learned from the sequence analysis of CVNHs are two-fold: first, the ligand-binding site is quite tolerant of mutations, while preserving at least structural integrity. Secondly, cyanovirin is a flexible module that can be altered significantly, for example by splitting the two internal repeats with an independently folded domain, and preserve its 3D structure. This versatility, while maintaining fold and stability, supports the choice of using cyanovirin as scaffold for extensive redesign of the binding pockets or oligomerization state.
Glycan recognition pocket
Although both domains have been shown to bind glycans, domain B has been extensively studied experimentally and computationally, with crystal structures showing watermediated hydrogen-bonding between the glycan and binding pocket residues. Despite the wealth of structural information, however, the origins of specificity in wt CVN and its mutants remains unclear. To address these issues, several groups have used computational methods to dissect the individual energetic contributions of each residue. MD simulations and MM/PBSA (molecular mechanics/Poisson-Boltzmann surface area) analysis are used extensively to investigate the relative binding free energies of several oligosaccharide ligands across two binding sites of CVN [42] [43] [44] [45] [46] [47] . These computational studies have elucidated the significance of backbone hydrogen bond interactions for sugar recognition [44] , and the role of Glu 41 and Arg 76 in conformational gating of dimannose binding to CVN [30, 47] . Moreover, in the context of complex oligosaccharide binding to CVN, a recent MD study suggested that the presence of a cis-peptide bond between Pro 51 and Ser 52 in monomeric state could attribute to the tendency of wt CVN to form domain-swapped dimers, and the analysis of the overall energetics of trimannose binding to both of the domains presents the critical role of all binding site functional groups [42] . However, glycan recognition is complicated further by hydration of the sugar, as water may play a role in recognition through watermediated hydrogen bonds and the structure of sugar [48] .
To predict binding affinities, our group developed a fast and efficient flexible docking method based on PRS (perturbation-response scanning) called BP-Dock (backbone perturbation-dock) [49] [50] [51] [52] . The method was benchmarked successfully by recapitulating the binding affinities of two very-well-characterized mutants of CVN: P51G-m4-CVN [29] and CVN mutDB [53] . The binding of dimannose in domain B of these two mutants differ in that the P51G-m4-CVN has high affinity for the sugar and CVN mutDB has no affinity for dimannose owing to the mutation of five polar residues in the binding pocket to small aliphatic residues. We further employed our flexible docking scheme to determine the contribution of those five individual residues to binding affinity for dimannose by computational single point mutants. The analysis of binding energies and hydrogenbond networks of these CVN mutants in complex with dimannose showed that a single E41A or E41G mutation leads to significant decrease in binding affinity. This effect is larger than what is expected by the loss of a single hydrogen bond to the ligand; our analysis revealed that the mutation leads to a complete reorganization of the hydrogen bonds in the binding cavity, leading to the loss of four side-chain hydrogen bonds (Figure 3 ). This prediction was later verified by experimental characterization of the mutants, which displayed dissociation constants in the millimolar range, in contrast with the low-micromolar dissociation constants for P51G-m4-CVN, despite conserved fold and stability. We have shown that by using BP-Dock we can very quickly and accurately determine relative binding affinities for designed mutants, allowing for the fast evaluation of new constructs 
Conclusion and outlook
CVN has proved to be an excellent model system for studying glycan lectin recognition. Work in our laboratory and others has shown that the potent anti-HIV activity of CVN is due to its multivalency and specificity for the branched ends of the oligomannoses that coat the envelope protein gp120. Recent research utilizing both experimental and computational methods has begun to unfold the contributing factors for the affinity and specificity for the Manα(1→2)Manα glycan moiety. The approach applied in our laboratory using BP-Dock integrated with experimental work has further elucidated the contributions of individual amino acids to affinity for dimannose in domain B and provides a platform to efficiently evaluate changes in the binding pocket. These tools should enable the design of novel glycan-binding agents based on CVN and tailored to other glycans of interest.
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